Novo Nordisk AS's positive top-line data for its oral semaglutide in the Phase III PIONEER 1 study in type 2 diabetes – the first of 10 studies to report – are reassuring in some ways, but raise questions about whether weight loss and compliance are good enough to carry the tablet version of the GLP-1 agonist.
The rest of the trials in the PIONEER development program, which involves more than 9,000 patients, are set to read...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)